The Robot That Fits Where Others Won't

Revolve Surgical's FDA-cleared table-mounted robot targets ambulatory surgery centers long priced out of robotic care

20 May 2026

Most operating rooms have never seen a robot. Revolve Surgical wants to change that, starting with the ones everyone else skipped.

On March 17, 2026, the company earned FDA 510(k) clearance for a table-mounted surgical robot with a zero-footprint design. Rather than anchoring to the floor like conventional systems, it attaches directly to the operating table. One person can set it up. No facility modifications required.

Ambulatory surgery centers have long been priced out of robotic surgery, blocked by steep capital costs and machines that demand dedicated square footage they don't have. Revolve's platform targets that gap directly. Clearance currently covers general surgery, with expanded laparoscopic approval expected before commercial launch following initial pilot studies.

Unity Health, a Canadian hospital system, has already signed on as the first clinical partner. Its VP of research and innovation called the system a natural fit for common procedures, and the institution becomes the first to put the technology into live clinical practice.

The company's pitch goes beyond hardware. "In surgery, there's no universally accessible platform," co-founder Alex Gordon has said. Backed by Y Combinator, Revolve frames its ambition as embedding physical AI capabilities across operating rooms at scale, not just at flagship academic centers where robots already cluster.

Millions of elective procedures now happen in outpatient settings each year. Robots remain concentrated in large hospitals. Whether pilot data and expanded clearance can confirm early promise across a wider range of procedures is the question that comes next. FDA clearance, for now, marks a credible entry into a market that has been waiting for a smaller answer.